Evidence map›Paper›PMID 40425697›Full record

ArticleNPJ precision oncology2025

Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study.

Damien Vasseur, Samuel Abbou, Ludovic Lacroix, Laurence Lamant, Noémie Pata-Merci, David Sibon, Francesco Facchinetti, Marc Deloger, Floriane Braye, Véronique Minard-Colin and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Damien Vasseur *Medical Biology and Pathology Department, Villejuif, France.
Samuel Abbou *Gustave Roussy Cancer Campus, Children and Adolescent Oncology Department, Villejuif, France.
Ludovic LacroixMedical Biology and Pathology Department, Villejuif, France.
Laurence LamantDepartment of Pathology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
Noémie Pata-MerciAMMICa UAR3655/US23, Villejuif, France.
David SibonLymphoid Malignancies Department, Henri Mondor University Hospital, AP-HP, Créteil, France.
Francesco FacchinettiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Marc DelogerBioinformatics Core Facility, Inserm US23, CNRS, Villejuif, France.
Floriane BrayeParis-Saclay University, Villejuif, France.
Véronique Minard-ColinGustave Roussy Cancer Campus, Children and Adolescent Oncology Department, Villejuif, France.
Laurence BrugièresGustave Roussy Cancer Campus, Children and Adolescent Oncology Department, Villejuif, France.
Etienne RouleauMedical Biology and Pathology Department, Villejuif, France.
Luc Friboulet *Paris-Saclay University, Villejuif, France.
Charlotte Rigaud *Gustave Roussy Cancer Campus, Children and Adolescent Oncology Department, Villejuif, France. charlotte.rigaud@gustaveroussy.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this multicenter study, we were able to detect circulating tumor DNA (ctDNA) in 87.5% of patients with the rare disease ALK + ALCL. Moreover, by analyzing ctDNA from samples collected at disease progression, we were able to identify resistance mutations to ALK inhibitors. Furthermore, ctDNA proved to be a valuable and consistent tool for monitoring minimal residual disease.

Identifiers

PMID40425697
PMCPMC12116725

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.